ClinicalTrials.gg
CompletedNCT03043313Updated Nov 26, 2024Results posted

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

A Phase 2 interventional study of Trastuzumab and Tucatinib in Metastatic Colorectal Adenocarcinoma, sponsored by Seagen Inc.. Completed at 56 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Colorectal Neoplasms by Pfizer — 6 open to participants now, 14 under way, 3 of them phase 3. Colorectal Neoplasms · Pfizer.

Enrollment
25th of 68
117 · median 72
Started
2017
with 1 other
Phase 2
21 of 73
1 open now
Registered
35th of 73
by date

Among the 73 studies in Colorectal Neoplasms by Pfizer, this one is the 25th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2017, is one of 21 in phase 2, and was the 35th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

6 of the 73 studies in Colorectal Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Colorectal Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body.

In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.

03

Conditions studied

  • Metastatic Colorectal Adenocarcinoma

Keywords

  • HER2
  • ERBB2
  • Colorectal cancer
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • and/or cytologically documented adenocarcinoma of the colon or rectum that is and/or unresectable
  • Unless , participants must have received and failed regimens containing the following agents: fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody (bevacizumab, ramucirumab, or ziv-aflibercept), and an anti-PD-(L)1 therapy (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins or is MSI-High.
  • Have progression of unresectable or metastatic CRC after the last systemic therapy, or be intolerant of last systemic therapy
  • Have RAS wild-type in primary or metastatic tumor tissue, based on expanded RAS testing
  • Willing and able to provide the most recently available tissue blocks obtained prior to treatment initiation. If is not available, then a newly-obtained baseline biopsy of an accessible tumor
  • Have confirmed -positive mCRC, as defined by having tumor tissue tested at a Clinical Laboratory Improvement Act (CLIA)-certified or International Organization for Standardization (ISO)-accredited laboratory, meeting at least one of the following criteria:

    • HER2+ overexpression (3+ immunohistochemistry [IHC]) by an FDA-approved or Conformité Européene (CE)-marked HER2 ICH test
    • HER2 2+ IHC is eligible if the tumor is amplified by an FDA-approved or CE-marked HER2 in situ hybridization assay (FISH or chromogenic in situ hybridization [CISH]))
    • HER2 (ERBB2) amplification by CLIA-certified or ISO-accredited next generation sequencing (NGS) sequencing assay
  • Have radiographically assessable by 1.1, with at least one site of disease that is measurable and that has not been previously irradiated; or, if the participant has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
  • (ECOG) performance status (PS) of 0, 1, or 2
  • greater than 3 months
  • Have adequate hematological, hepatic, renal, coagulation, and cardiac function

Exclusion criteria

Exclusion Criteria

  • Previous treatment with anti- targeting therapy
  • Previous treatment with any systemic anticancer therapy, non-central nervous system radiation, or experimental agent within 3 weeks of first dose of study treatment
  • Toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:

    • Alopecia and neuropathy, which must have resolved to ≤ Grade 2
    • Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of occurrence, and must have resolved completely
    • Anemia, which must have resolved to ≤ Grade 2
    • Decreased ANC, which must have resolved to ≤ Grade 2
  • Have cardiopulmonary disease
  • Have known myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or cardiac surgery within 6 months prior to first dose of study treatment
  • Major surgical procedure, open , or significant traumatic injury ≤28 days prior to enrollment (≤56 days for hepatectomy, open thoracotomy, or major neurosurgery) or anticipation of need for major surgical procedure during the study
  • Serious, non-healing wound, ulcer, or bone fracture
  • Known to be positive for by surface antigen expression
  • Known to have active infection

    • Exception for participants with a documented sustained virologic response of 12 weeks
  • Known to be positive for (HIV)
  • Subjects who are pregnant, breastfeeding, or planning a pregnancy
  • Inability to swallow pills or any significant gastrointestinal disease which would preclude the adequate oral absorption of medications
  • Have used strong CYP2C8 inhibitor within 5 half-lives of the inhibitor, or have used a strong CYP2C8 or inducer within 5 days prior to first dose of study treatment
  • History of another within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.

    • Exceptions are malignancies with a negligible risk of or death
  • Subjects with known active

    • Irradiated or resected lesions are permitted, provided the lesions are fully treated and inactive, subject is asymptomatic, and no have been administered for at least 30 days
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    Cohort A: Tucatinib + Trastuzumab

    Non-randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.

    Drug: Trastuzumab · Drug: Tucatinib

  • Experimental
    Cohort B: Tucatinib + Trastuzumab

    Randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.

    Drug: Trastuzumab · Drug: Tucatinib

  • Experimental
    Cohort C: Tucatinib Monotherapy

    Randomized cohort. Participants take tucatinib twice per orally every day. Participants who do not respond to therapy may have the option to receive tucatinib and trastuzumab.

    Drug: Tucatinib

Interventions

  • Given intravenously (into the vein; IV)

    Also known as: Herceptin

  • Given orally

    Also known as: ARRY-380, ONT-380, TUKYSA

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B

    cORR was defined as the percentage of participants with confirmed CR or PR according to RECIST v1.1. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to less than (\<)1.0 centimeter (cm). PR was defined as at least a 30 percentage (%) decrease in post-baseline sum of the diameters (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the baseline sum of diameters.

    Time frame: Up to 46.6 months

Secondary outcomes

  1. ORR by 12 Weeks of Treatment Per RECIST v1.1 According to BICR Assessment

    ORR per BICR by 12 Weeks was defined as the percentage of participants with CR or PR by 12 weeks of treatment, and before time of crossover (Cohort C), whichever came earlier. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to more than \<1.0 cm. PR was defined as at least a 30% decrease in post-baseline sum of the diameters (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the baseline sum of diameter.

    Time frame: Up to 3 months

  2. Duration of Response (DOR) Per RECIST v1.1 According to BICR Assessment

    DOR was defined as the time from the first objective response (CR or PR that is subsequently confirmed) to documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to more than \<1.0 cm. PR was defined as at least a 30% decrease in post-baseline sum of the diameters (PBSD) (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the BSD. PD was defined as: at least one new malignant lesion, which also includes any lymph node that was normal at baseline (\<1.0 cm short axis) and increased to more than or equal to (\>=)1.0 cm short axis during follow-up or at least a 20% increase in PBSD taking as reference the minimum sum of the diameters (MSD). In addition, the PBSD must also demonstrate an absolute increase of at least 0.5 cm from the MSD.

    Time frame: Up to 64.1 months

  3. Progression-Free Survival (PFS) Per RECIST v1.1 According to BICR Assessment for Pooled Cohorts A+B

    PFS was defined as the time from start of study treatment (Cohort A) or date of randomization (Cohort B) to documented disease progression (as determined by BICR per RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as: at least one new malignant lesion, which also included any lymph node that was normal at baseline (\<1.0 cm short axis) and increased to \>=1.0 cm short axis during follow-up or at least a 20% increase in post-baseline sum of the diameters (PBSD) taking as reference the minimum sum of the diameters (MSD). In addition, the PBSD must also demonstrate an absolute increase of at least 0.5 cm from the MSD.

    Time frame: Up to 64.1 months

  4. Overall Survival (OS) in Pooled Cohorts A+B

    OS was defined as the time from start of study treatment (Cohort A) or randomization (Cohort B) to date of death due to any cause.

    Time frame: Up to 71.8 months

  5. Number of Participants With Adverse Events (AEs): Interim Analysis

    AE: Any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs): Events that were new or worsened on or after receiving the first dose of study treatment (tucatinib or trastuzumab) and up through 30 days after the last dose of study treatment (tucatinib or trastuzumab). Serious AE (SAE): An event that at any dose led to death; life-threatening; required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Relatedness was judged by investigator According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G) 3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE.

    Time frame: Up to 49.3 months

  6. Number of Participants With AEs: Final Analysis

    AE: Any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs): Events that were new or worsened on or after receiving the first dose of study treatment (tucatinib or trastuzumab) and up through 30 days after the last dose of study treatment (tucatinib or trastuzumab). SAE: An event that at any dose led to death; life-threatening; required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Relatedness was judged by investigator According to NCI CTCAE version 4.03: Grade(G) 3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE.

    Time frame: Up to 65.1 months

  7. Number of Participants With AEs Resulting in Dose Modification: Interim Analysis

    Dose modification included dose reduction and dose withheld by investigator due to AEs. Dose holds were defined as any instances where planned administration of the study drug was temporarily withheld or interrupted at the direction of the treating physician. Dose reductions of trastuzumab were not allowed; if trastuzumab could not be restarted after being held for a TEAE, it was discontinued.

    Time frame: Up to 49.3 months

  8. Number of Participants With AEs Resulting in Dose Modification: Final Analysis

    Dose modification included dose reduction and dose withheld by investigator due to AEs. Dose holds were defined as any instances where planned administration of the study drug was temporarily withheld or interrupted at the direction of the treating physician. Dose reductions of trastuzumab were not allowed; if trastuzumab could not be restarted after being held for a TEAE, it was discontinued. Drug interruption included infusion interrupted (full dose received within 24hrs).

    Time frame: Up to 65.1 months

  9. Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology): Interim Analysis

    The following hematology laboratory parameters were assessed: Hemoglobin decreased; leukocytes decreased; neutrophils decreased and Platelets decreased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v4.03 was used for the lab parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

    Time frame: Up to 49.3 months

  10. Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology): Final Analysis

    The following hematology laboratory parameters were assessed: Hemoglobin decreased; hemoglobin increased; leukocytes decreased; lymphocytes decreased; neutrophils decreased and Platelets decreased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v4.03 was used for the lab parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

    Time frame: Up to 65.1 months

  11. Number of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry): Interim Analysis

    The following chemistry laboratory parameters were assessed: Potassium increased; potassium decreased; aspartate aminotransferase increased; creatinine increased; alkaline phosphatase increased; total bilirubin increased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v5.0 was used for creatinine increased. NCI CTCAE v4.03 was used for the other laboratory parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

    Time frame: Up to 49.3 months

  12. Number of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry): Final Analysis

    The following chemistry laboratory parameters were assessed: Potassium increased; potassium decreased; aspartate aminotransferase increased; creatinine increased; alkaline phosphatase increased; total bilirubin increased; albumin decreased; calcium corrected for albumin decreased; calcium corrected for albumin increased; glomerular filtration rate (GFR), estimated decreased; glucose decreased; glucose increased; sodium decreased; sodium increased; calcium and ionized increased. Treatment emergent laboratory abnormalities: Abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v5.0 used for creatinine increased. NCI CTCAE v4.03 used for the other laboratory parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

    Time frame: Up to 65.1 months

  13. Number of Participants With Clinically Significant Vital Signs: Final Analysis

    Vital signs included temperature, oxygen saturation, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate and weight. Vital signs were considered clinically significant: temperature: \>= 38 degree Celsius (C); oxygen saturation less than (\<)88%; SBP \>=120 millimeters of mercury (mmHg) or DBP \>=80 mmHg; SBP \>=140 mmHg or DBP \>=90 mmHg; SBP \>=160 mmHg or DBP \>=100 mmHg and heart rate \>100 beats per minute (bpm) and maximum decrease from baseline in weight in kilograms (kg).

    Time frame: Up to 65.1 months

07

Results

Posted Apr 18, 2023

Participant flow

A total of 117 participants were enrolled at a total of 56 sites in the United States, Italy, France, Belgium, and Spain. The date of first participant enrollment was 23-Jun-2017. The date of last participant randomization was 02-Nov-2023.

Participant flow — Overall Study
MilestoneTucatinib+Trastuzumab (Cohort A)Tucatinib+Trastuzumab (Cohort B)Tucatinib Monotherapy (Cohort C)
Started454131
Completed000
Not completed454131
Withdrew: Withdrawal by subject511
Withdrew: Lost to follow-up110
Withdrew: Death282617
Withdrew: Participation terminated by sponsor111313

Outcome measures

PrimaryConfirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B

cORR was defined as the percentage of participants with confirmed CR or PR according to RECIST v1.1. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to less than (\<)1.0 centimeter (cm). PR was defined as at least a 30 percentage (%) decrease in post-baseline sum of the diameters (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the baseline sum of diameters.

Time frame:
Up to 46.6 months
Reported as:
Number · Percentage of Participants
Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B
Percentage of ParticipantsTucatinib+Trastuzumab (Cohorts A+B)
Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B39.3 (28.8 to 50.5)
SecondaryORR by 12 Weeks of Treatment Per RECIST v1.1 According to BICR Assessment

ORR per BICR by 12 Weeks was defined as the percentage of participants with CR or PR by 12 weeks of treatment, and before time of crossover (Cohort C), whichever came earlier. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to more than \<1.0 cm. PR was defined as at least a 30% decrease in post-baseline sum of the diameters (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the baseline sum of diameter.

Time frame:
Up to 3 months
Reported as:
Number · Percentage of Participants
ORR by 12 Weeks of Treatment Per RECIST v1.1 According to BICR Assessment
Percentage of ParticipantsTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Pre-Crossover (Cohort C)
ORR by 12 Weeks of Treatment Per RECIST v1.1 According to BICR Assessment28.6 (19.2 to 39.5)3.3 (0.1 to 17.2)
SecondaryDuration of Response (DOR) Per RECIST v1.1 According to BICR Assessment

DOR was defined as the time from the first objective response (CR or PR that is subsequently confirmed) to documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as the disappearance of all target lesions and each target lymph node must have reduction in short axis to more than \<1.0 cm. PR was defined as at least a 30% decrease in post-baseline sum of the diameters (PBSD) (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking as reference the BSD. PD was defined as: at least one new malignant lesion, which also includes any lymph node that was normal at baseline (\<1.0 cm short axis) and increased to more than or equal to (\>=)1.0 cm short axis during follow-up or at least a 20% increase in PBSD taking as reference the minimum sum of the diameters (MSD). In addition, the PBSD must also demonstrate an absolute increase of at least 0.5 cm from the MSD.

Time frame:
Up to 64.1 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST v1.1 According to BICR Assessment
MonthsTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Pre-Crossover (Cohort C)
Duration of Response (DOR) Per RECIST v1.1 According to BICR Assessment15.2 (8.9 to 20.5)NA (NA to NA)
SecondaryProgression-Free Survival (PFS) Per RECIST v1.1 According to BICR Assessment for Pooled Cohorts A+B

PFS was defined as the time from start of study treatment (Cohort A) or date of randomization (Cohort B) to documented disease progression (as determined by BICR per RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as: at least one new malignant lesion, which also included any lymph node that was normal at baseline (\<1.0 cm short axis) and increased to \>=1.0 cm short axis during follow-up or at least a 20% increase in post-baseline sum of the diameters (PBSD) taking as reference the minimum sum of the diameters (MSD). In addition, the PBSD must also demonstrate an absolute increase of at least 0.5 cm from the MSD.

Time frame:
Up to 64.1 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Per RECIST v1.1 According to BICR Assessment for Pooled Cohorts A+B
MonthsTucatinib+Trastuzumab (Cohorts A+B)
Progression-Free Survival (PFS) Per RECIST v1.1 According to BICR Assessment for Pooled Cohorts A+B8.1 (4.2 to 10.2)
SecondaryOverall Survival (OS) in Pooled Cohorts A+B

OS was defined as the time from start of study treatment (Cohort A) or randomization (Cohort B) to date of death due to any cause.

Time frame:
Up to 71.8 months
Reported as:
Median · Months
Overall Survival (OS) in Pooled Cohorts A+B
MonthsTucatinib+Trastuzumab (Cohorts A+B)
Overall Survival (OS) in Pooled Cohorts A+B23.9 (18.7 to 28.3)
SecondaryNumber of Participants With Adverse Events (AEs): Interim Analysis

AE: Any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs): Events that were new or worsened on or after receiving the first dose of study treatment (tucatinib or trastuzumab) and up through 30 days after the last dose of study treatment (tucatinib or trastuzumab). Serious AE (SAE): An event that at any dose led to death; life-threatening; required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Relatedness was judged by investigator According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G) 3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE.

Time frame:
Up to 49.3 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs): Interim Analysis
ParticipantsTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Pre-Crossover (Cohort C)
Any TEAE8228
Tucatinib-related TEAE6322
Trastuzumab-related TEAE58NA
Any grade 3-5 TEAE338
Trastuzumab-related grade 3-5 TEAE6NA
Tucatinib-related grade 3-5 TEAE82
Any Treatment-Emergent Serious AE (TESAE)193
Tucatinib-related TESAE31
Trastuzumab-related TESAE2NA
TEAE leading to death00
Discontinuation of any study treatment due to TEAE50
Discontinuation of tucatinib due to TEAE50
Discontinuation of tucatinib due to tucatinib-related TEAE20
Discontinuation of trastuzumab due to TEAE3NA
Discontinuation of trastuzumab due to trastuzumab-related TEAE0NA
SecondaryNumber of Participants With AEs: Final Analysis

AE: Any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs): Events that were new or worsened on or after receiving the first dose of study treatment (tucatinib or trastuzumab) and up through 30 days after the last dose of study treatment (tucatinib or trastuzumab). SAE: An event that at any dose led to death; life-threatening; required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Relatedness was judged by investigator According to NCI CTCAE version 4.03: Grade(G) 3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE.

Time frame:
Up to 65.1 months
Reported as:
Count of participants · Participants
Number of Participants With AEs: Final Analysis
ParticipantsTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Post-Crossover (Cohort C)
Any TEAE8223
Tucatinib-related TEAE6415
Trastuzumab-related TEAE5913
More than or equal to (>=) Grade 3 TEAE359
Tucatinib-related >= grade 3 TEAE82
Trastuzumab-related >= grade 3 TEAE62
Any Treatment-Emergent Serious AE (TESAE)206
Tucatinib-related TESAE30
Trastuzumab-related TESAE22
TEAE leading to death00
Discontinuation of any study treatment due to TEAE52
Discontinuation of tucatinib due to treatment-related TEAE22
Discontinuation of tucatinib due to tucatinib-related TEAE22
Discontinuation of trastuzumab due to treatment-related TEAE11
Discontinuation of trastuzumab due to trastuzumab-related TEAE00
SecondaryNumber of Participants With AEs Resulting in Dose Modification: Interim Analysis

Dose modification included dose reduction and dose withheld by investigator due to AEs. Dose holds were defined as any instances where planned administration of the study drug was temporarily withheld or interrupted at the direction of the treating physician. Dose reductions of trastuzumab were not allowed; if trastuzumab could not be restarted after being held for a TEAE, it was discontinued.

Time frame:
Up to 49.3 months
Reported as:
Count of participants · Participants
Number of Participants With AEs Resulting in Dose Modification: Interim Analysis
ParticipantsTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Pre-Crossover (Cohort C)
Tucatinib dose held203
Tucatinib dose reduced81
Trastuzumab dose held24NA
Trastuzumab infusion interrupted (received full dose within 24 hrs)6NA
Trastuzumab infusion stopped early (full dose not received)1NA
SecondaryNumber of Participants With AEs Resulting in Dose Modification: Final Analysis

Dose modification included dose reduction and dose withheld by investigator due to AEs. Dose holds were defined as any instances where planned administration of the study drug was temporarily withheld or interrupted at the direction of the treating physician. Dose reductions of trastuzumab were not allowed; if trastuzumab could not be restarted after being held for a TEAE, it was discontinued. Drug interruption included infusion interrupted (full dose received within 24hrs).

Time frame:
Up to 65.1 months
Reported as:
Count of participants · Participants
Number of Participants With AEs Resulting in Dose Modification: Final Analysis
ParticipantsTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Post-Crossover (Cohort C)
Tucatinib dose held237
Tucatinib dose reduced92
Trastuzumab dose held272
Trastuzumab infusion interrupted60
SecondaryNumber of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology): Interim Analysis

The following hematology laboratory parameters were assessed: Hemoglobin decreased; leukocytes decreased; neutrophils decreased and Platelets decreased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v4.03 was used for the lab parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

Time frame:
Up to 49.3 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology): Interim Analysis
ParticipantsTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Pre-Crossover (Cohort C)
Hemoglobin decreased, Grade 1286
Hemoglobin decreased, Grade 282
Hemoglobin decreased, Grade 330
Hemoglobin decreased, Grade 400
Leukocytes decreased, Grade 1143
Leukocytes decreased, Grade 250
Leukocytes decreased, Grade 300
Leukocytes decreased, Grade 400
Neutrophils decreased, Grade 161
Neutrophils decreased, Grade 221
Neutrophils decreased, Grade 300
Neutrophils decreased, Grade 400
Platelets decreased, Grade 1111
Platelets decreased, Grade 222
Platelets decreased, Grade 300
Platelets decreased, Grade 400
SecondaryNumber of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology): Final Analysis

The following hematology laboratory parameters were assessed: Hemoglobin decreased; hemoglobin increased; leukocytes decreased; lymphocytes decreased; neutrophils decreased and Platelets decreased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v4.03 was used for the lab parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

Time frame:
Up to 65.1 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology): Final Analysis
ParticipantsTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Post-Crossover (Cohort C)
Hemoglobin decreased, All grades429
Hemoglobin decreased, Grade 330
Hemoglobin decreased, Grade 400
Hemoglobin increased: All grades30
Hemoglobin increased: Grade 300
Hemoglobin increased: Grade 400
Leukocytes decreased, All grades215
Leukocytes decreased, Grade 300
Leukocytes decreased, Grade 400
Lymphocytes decreased, All grades2511
Lymphocytes decreased, Grade 361
Lymphocytes decreased, Grade 400
Neutrophils decreased: All grades100
Neutrophils decreased: Grade 300
Neutrophils decreased: Grade 400
Platelets decreased, All grades154
Platelets decreased, Grade 300
Platelets decreased, Grade 401
SecondaryNumber of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry): Interim Analysis

The following chemistry laboratory parameters were assessed: Potassium increased; potassium decreased; aspartate aminotransferase increased; creatinine increased; alkaline phosphatase increased; total bilirubin increased. Treatment emergent laboratory abnormalities were defined as abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v5.0 was used for creatinine increased. NCI CTCAE v4.03 was used for the other laboratory parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

Time frame:
Up to 49.3 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry): Interim Analysis
ParticipantsTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Pre-Crossover (Cohort C)
Potassium increased, Grade 151
Potassium increased, Grade 210
Potassium increased, Grade 301
Potassium increased, Grade 400
Potassium decreased, Grade 1133
Potassium decreased, Grade 200
Potassium decreased, Grade 311
Potassium decreased, Grade 400
Aspartate Aminotransferase increased, Grade 1206
Aspartate Aminotransferase increased, Grade 230
Aspartate Aminotransferase increased, Grade 322
Aspartate Aminotransferase increased, Grade 430
Alanine Aminotransferase increased, Grade 1314
Alanine Aminotransferase increased, Grade 242
Alanine Aminotransferase increased, Grade 322
Alanine Aminotransferase increased, Grade 420
Creatinine increased, Grade 1389
Creatinine increased, Grade 2110
Creatinine increased, Grade 300
Creatinine increased, Grade 400
Alkaline Phosphatase increased, Grade 1164
Alkaline Phosphatase increased, Grade 242
Alkaline Phosphatase increased, Grade 310
Alkaline Phosphatase increased, Grade 400
Total Bilirubin increased, Grade 1146
Total Bilirubin increased, Grade 250
Total Bilirubin increased, Grade 330
Total Bilirubin increased, Grade 420
SecondaryNumber of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry): Final Analysis

The following chemistry laboratory parameters were assessed: Potassium increased; potassium decreased; aspartate aminotransferase increased; creatinine increased; alkaline phosphatase increased; total bilirubin increased; albumin decreased; calcium corrected for albumin decreased; calcium corrected for albumin increased; glomerular filtration rate (GFR), estimated decreased; glucose decreased; glucose increased; sodium decreased; sodium increased; calcium and ionized increased. Treatment emergent laboratory abnormalities: Abnormalities that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. NCI CTCAE v5.0 used for creatinine increased. NCI CTCAE v4.03 used for the other laboratory parameters. Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.

Time frame:
Up to 65.1 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry): Final Analysis
ParticipantsTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Post-Crossover (Cohort C)
Potassium increased, All grades64
Potassium increased, Grade 300
Potassium increased, Grade 400
Potassium decreased, All grades154
Potassium decreased, Grade 310
Potassium decreased, Grade 400
Aspartate Aminotransferase increased, All grades299
Aspartate Aminotransferase increased, Grade 323
Aspartate Aminotransferase increased, Grade 430
Alanine Aminotransferase increased, All grades397
Alanine Aminotransferase increased, Grade 322
Alanine Aminotransferase increased, Grade 420
Creatinine increased, All grades5010
Creatinine increased, Grade 300
Creatinine increased, Grade 400
Alkaline Phosphatase increased, All grades213
Alkaline Phosphatase increased, Grade 310
Alkaline Phosphatase increased, Grade 400
Total Bilirubin increased, All grades254
Total Bilirubin increased, Grade 330
Total Bilirubin increased, Grade 420
Albumin decreased, All grades238
Albumin decreased, Grade 310
Albumin decreased, Grade 400
Calcium Corrected for Albumin decreased, All grades115
Calcium Corrected for Albumin decreased, Grade 300
Calcium Corrected for Albumin decreased, Grade 400
Calcium Corrected for Albumin increased, All grades85
Calcium Corrected for Albumin increased, Grade 300
Calcium Corrected for Albumin increased, Grade 400
Glomerular Filtration Rate, Estimated decreased, All grades516
Glomerular Filtration Rate, Estimated decreased, Grade 360
Glomerular Filtration Rate, Estimated decreased, Grade 400
Glucose decreased, All grades101
Glucose decreased, Grade 300
Glucose decreased, Grade 400
Glucose increased, All grades489
Glucose increased, Grade 320
Glucose increased, Grade 400
Sodium decreased, All grades181
Sodium decreased, Grade 350
Sodium decreased, Grade 400
Sodium increased, All grades74
Sodium increased, Grade 300
Sodium increased, Grade 400
Calcium, Ionized increased: All grades20
Calcium, Ionized increased: Grade 300
Calcium, Ionized increased: Grade 400
SecondaryNumber of Participants With Clinically Significant Vital Signs: Final Analysis

Vital signs included temperature, oxygen saturation, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate and weight. Vital signs were considered clinically significant: temperature: \>= 38 degree Celsius (C); oxygen saturation less than (\<)88%; SBP \>=120 millimeters of mercury (mmHg) or DBP \>=80 mmHg; SBP \>=140 mmHg or DBP \>=90 mmHg; SBP \>=160 mmHg or DBP \>=100 mmHg and heart rate \>100 beats per minute (bpm) and maximum decrease from baseline in weight in kilograms (kg).

Time frame:
Up to 65.1 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Signs: Final Analysis
ParticipantsTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Post-Crossover (Cohort C)
Temperature >=38 degree C10
Oxygen saturation <88%80
SBP >= 120 mmHg or DBP >= 80 mmHg8027
SBP >= 140 mmHg or DBP >= 90 mmHg4913
SBP >= 160 mmHg or DBP >= 100 mmHg214
Heart rate > 100 bpm265
Maximum decrease from baseline in weight (kg)6523

Adverse events

Collected over All-cause mortality: From start of study treatment to death by any cause (maximum up to 71.8 months); adverse events were followed during the safety reporting period (from Day 1 through 30 days after the last dose of study treatment) maximum up to 65.1 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tucatinib+Trastuzumab (Cohorts A+B)54/86 (62.8%)20/86 (23.3%)82/86 (95.3%)
Tucatinib Pre-Crossover (Cohort C)2/31 (6.5%)3/30 (10%)28/30 (93.3%)
Tucatinib Post-Crossover (Cohort C)15/28 (53.6%)6/28 (21.4%)23/28 (82.1%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Pre-Crossover (Cohort C)Tucatinib Post-Crossover (Cohort C)
Cardiac failureCardiac disorders0/860/301/28
ConstipationGastrointestinal disorders0/860/301/28
CholecystitisHepatobiliary disorders0/860/301/28
Humerus fractureInjury, poisoning and procedural complications0/860/301/28
Radius fractureInjury, poisoning and procedural complications0/860/301/28
Ulna fractureInjury, poisoning and procedural complications0/860/301/28
Ejection fraction decreasedInvestigations0/860/301/28
Peripheral sensorimotor neuropathyNervous system disorders0/860/301/28
Acute kidney injuryRenal and urinary disorders1/860/301/28
Large intestinal obstructionGastrointestinal disorders3/860/300/28
Most frequent other events
Showing 10 of 148
Most frequent other events
EventTucatinib+Trastuzumab (Cohorts A+B)Tucatinib Pre-Crossover (Cohort C)Tucatinib Post-Crossover (Cohort C)
DiarrhoeaGastrointestinal disorders57/8610/3011/28
FatigueGeneral disorders37/866/303/28
NauseaGastrointestinal disorders29/865/302/28
PyrexiaGeneral disorders18/863/306/28
Back painMusculoskeletal and connective tissue disorders16/861/306/28
Infusion related reactionInjury, poisoning and procedural complications18/860/304/28
Abdominal painGastrointestinal disorders11/866/302/28
Decreased appetiteMetabolism and nutrition disorders17/864/302/28
Dermatitis acneiformSkin and subcutaneous tissue disorders17/862/300/28
ChillsGeneral disorders16/860/302/28

Baseline characteristics

The Full Analysis Set included all participants who were enrolled and received any amount of study treatment and had human epidermal growth factor receptor 2+ (HER2+) tumors as defined by one or more protocol required local tests.

Age, Continuous
Age, Continuous(Years)Tucatinib+Trastuzumab (Cohort A)Tucatinib+Trastuzumab (Cohort B)Tucatinib Monotherapy (Cohort C)Total
Median52 (24 to 71)57 (31 to 77)59.5 (29 to 75)56 (24 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Tucatinib+Trastuzumab (Cohort A)Tucatinib+Trastuzumab (Cohort B)Tucatinib Monotherapy (Cohort C)Total
Female19141548
Male26251566
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tucatinib+Trastuzumab (Cohort A)Tucatinib+Trastuzumab (Cohort B)Tucatinib Monotherapy (Cohort C)Total
Hispanic or Latino2114
Not Hispanic or Latino35292589
Unknown or Not Reported89421
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tucatinib+Trastuzumab (Cohort A)Tucatinib+Trastuzumab (Cohort B)Tucatinib Monotherapy (Cohort C)Total
American Indian or Alaska Native1001
Asian2103
Native Hawaiian or Other Pacific Islander0000
Black or African American1236
White37282388
More than one race1001
Unknown or Not Reported38415
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Tucatinib+Trastuzumab (Cohort A)Tucatinib+Trastuzumab (Cohort B)Tucatinib Monotherapy (Cohort C)Total
Grade 024261767
Grade 120111344
Grade 21203
Region of Enrollment
Region of Enrollment(Participants)Tucatinib+Trastuzumab (Cohort A)Tucatinib+Trastuzumab (Cohort B)Tucatinib Monotherapy (Cohort C)Total
North America45241685
Europe0151429
08

Study locations

56 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • Keck Medical Center / University of Southern California
    Los Angeles, California 90033, United States
  • Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute
    Los Angeles, California 90048, United States
  • Stanford University School of Medicine
    Palo Alto, California 94304, United States
  • Saint Joseph Heritage Medical Group
    Santa Rosa, California 95403, United States
  • Rocky Mountain Cancer Centers - Aurora
    Aurora, Colorado 80012, United States
  • Lombardi Cancer Center / Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Florida Cancer Specialists - South Region
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists - North Region
    Saint Petersburg, Florida 33705, United States
  • Winship Cancer Institute / Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637-1470, United States
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute / Wayne State University
    Detroit, Michigan 48201, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14203, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Case Western Reserve University / University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Northwest Cancer Specialists, P.C.
    Portland, Oregon 97227, United States
  • Oregon Health and Science University
    Portland, Oregon 97239-3098, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Tennessee Oncology-Nashville/Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Texas Oncology - Beaumont
    Beaumont, Texas 77702-1449, United States
  • Texas Oncology - Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Joe Arrington Cancer Research and Treatment Center
    Lubbock, Texas 79410, United States
  • Texas Oncology - McAllen
    McAllen, Texas 78503, United States
  • Texas Oncology - San Antonio Medical Center
    San Antonio, Texas 78240, United States
  • Texas Oncology - Tyler
    Tyler, Texas 75702, United States
  • Huntsman Cancer Institute/University of Utah
    Salt Lake City, Utah 84112, United States
  • Providence Regional Medical Center Everett
    Everett, Washington 98201, United States
  • Seattle Cancer Care Alliance / University of Washington
    Seattle, Washington 98109-1023, United States
  • Aurora Research Institute Cancer Center
    Milwaukee, Wisconsin 53215, United States
  • Cliniques Universitaires Saint Luc
    Brussels, Other 1200, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, Other 2650, Belgium
  • UZ Leuven campus Gasthuisberg
    Leuven, Other 3000, Belgium
  • Hospitalier Jean Minjoz
    Besancon, Other 25030, France
  • Center Georges Francois Leclerc
    Dijon, Other 21000, France
  • Hôpital Franco-Britannique - Fondation Cognacq-Jay
    Levallois-Perret, Other 92300, France
  • Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes
    Lyon, Other 69373, France
  • Hopital Saint-Antoine
    Paris, Other 75012, France
  • Instituto Europeo di Oncologia
    Milan, Other 20141, Italy
  • Niguarda Ca' Granda Hospital
    Milan, Other 20162, Italy
  • Azienda Ospedaliero-Universitaria Pisana - Ospedale S. Chiara
    Pisa, Other 56126, Italy
  • Hospital Universitario Vall d'Hebron
    Barcelona, Other 08035, Spain
  • Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
    L'Hospitalet de Llobregat, Other 08907, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, Other 28007, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, Other 46010, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Mar 2022, 57 months.

Results were first posted in Apr 2023, 1 year after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 57 months is above that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2017
First posted
Feb 6, 2017
StartActual
Jun 23, 2017
Primary completionActual
Mar 28, 2022
CompletionActual
Nov 2, 2023
Results first posted
Apr 18, 2023
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03043313
Lead sponsor
Seagen Inc.
Collaborators
National Cancer Institute (NCI), Academic and Community Cancer Research United
Responsible party
Sponsor
First posted
Feb 6, 2017
Start date
Jun 23, 2017
Primary completion
Mar 28, 2022
Completion
Nov 2, 2023
Results posted
Apr 18, 2023
Last update
Nov 26, 2024

Study contacts

John H Strickler
study chair · Academic and Community Cancer Research United
Jorge Ramos, DO
study director · Seagen Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucatinib

Start the discussion